Billionaire money managers reduced their holdings in these popular stocks last quarter, but was it a smart move?
Offhand comments from Abbott's CEO, and a confusing statement from Alere makes a pending acquisition doubtful.
The biotech's numbers are meaningless, but an update on one of its programs sent the stock down.
Less-than-convincing comments from acquirer Abbott Labs are causing a sell-off.
Our healthcare contributors think these five stocks might be on big pharma's shopping list.
It was a good week for healthcare ETFs, but this one fund put up a stellar performance.
The stock market was lucky to get back to breakeven, but these stocks soared. Find out why.
A win and loss for marijuana, a big advance in Alzheimer's disease, and the next big thing are among some of the market-moving things I expect to see happen this year.
Pfizer's stock is up 4% year-to-date, but this event was a clear disappointment for its shareholders in 2015.
Early human clinical trial results suggest that a better drug for lowering bad cholesterol may be on the horizon.